Clinical Trial

Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas

Study acronym: PTCL-SEQ
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of genes (NGS), in a population of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-13; most recent amendment 2026-02-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-12-29
Trial Details
NCT Number NCT06089941
Lead Sponsor Centre Henri Becquerel
Collaborators: IDEOGEN
Conditions Peripheral T Cell Lymphoma
Enrollment 45 participants
Start Date 2024-01-01
Primary Completion 2025-11-04 (estimated)
Study Completion 2026-11-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-20